PE13262015A1 - pharmaceutical compositions comprising betulin derivatives - Google Patents

pharmaceutical compositions comprising betulin derivatives

Info

Publication number
PE13262015A1
PE13262015A1 PE2015000924A PE0009242015A PE13262015A1 PE 13262015 A1 PE13262015 A1 PE 13262015A1 PE 2015000924 A PE2015000924 A PE 2015000924A PE 0009242015 A PE0009242015 A PE 0009242015A PE 13262015 A1 PE13262015 A1 PE 13262015A1
Authority
PE
Peru
Prior art keywords
pharmaceutical compositions
11a
5b
5a
3a
Prior art date
Application number
PE2015000924A
Other languages
Spanish (es)
Inventor
Shenshen Cai
Brian Alvin Johns
Andrew Spaltenstein
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201261737177P priority Critical
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Publication of PE13262015A1 publication Critical patent/PE13262015A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids

Abstract

Referida a composiciones farmaceuticas de accion prolongada de derivados de betulina o sales farmaceuticamente aceptables de los mismos. Refers to pharmaceutical compositions of prolonged action betulin derivatives or pharmaceutically acceptable salts thereof. Tales como el acido 4-(((3aR, 5aR, 5bR, 7aR, 9s, 11aR, 11bR, 13aS)-3a-((R)-2-((4-clorobencil)(2-(dimetilamino)etil)amino)-1-hidroxietil)-1-isopropil-5a, 5b, 8, 8, 11a-pentametil-2-oxo-3, 3a, 4, 5, 5a, 5b, 6, 7, 7a, 8, 9, 10, 11, 11a, 11b, 12, 13, 13a-octadecahidro-2H-ciclopenta[a]crisen-9-il-)oxi)-2,2-dimetil-4-oxobutanoico de formula I; Such as 4 - (((3aR, 5aR, 5BR, 7aR, 9S, 11aR, 11bR, 13aS) -3a - ((R) -2 - ((4-chlorobenzyl) (2- (dimethylamino) ethyl) amino ) -1-hydroxyethyl) -1-isopropyl-5a, 5b, 8, 8, 11a-pentamethyl-2-oxo-3, 3a, 4, 5, 5a, 5b, 6, 7, 7a, 8, 9, 10 , 11, 11a, 11b, 12, 13, 13a-octadecahidro-2H-cyclopenta [a] crisen-9-yl-) oxy) -2,2-dimethyl-4-oxobutanoic acid of formula I; donde dicha composicion comprende un sistema tensoactivo el cual comprende esteres de acido graso de sorbitan polioxietileno, poloxameros, aceite de ricino polietoxilado, entre otros y es util en el tratamiento o prevencion de infecciones por virus de inmunodeficiencia humana (VIH) wherein said composition comprises a surfactant system comprising fatty acid esters, polyoxyethylene sorbitan, poloxamers, polyethoxylated castor oil, etc. and is useful in the treatment or prevention of infections by human immunodeficiency virus (HIV)
PE2015000924A 2012-12-14 2013-12-14 pharmaceutical compositions comprising betulin derivatives PE13262015A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US201261737177P true 2012-12-14 2012-12-14

Publications (1)

Publication Number Publication Date
PE13262015A1 true PE13262015A1 (en) 2015-10-12

Family

ID=50935020

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000924A PE13262015A1 (en) 2012-12-14 2013-12-14 pharmaceutical compositions comprising betulin derivatives

Country Status (20)

Country Link
US (2) US9795619B2 (en)
EP (1) EP2931285A4 (en)
JP (1) JP2016503030A (en)
KR (1) KR20150093819A (en)
CN (1) CN104902905A (en)
AU (1) AU2013358897B2 (en)
BR (1) BR112015013695A2 (en)
CA (1) CA2893959A1 (en)
CL (1) CL2015001660A1 (en)
CR (1) CR20150313A (en)
EA (1) EA201590862A1 (en)
HK (1) HK1209638A1 (en)
IL (1) IL238807D0 (en)
MA (1) MA38182A1 (en)
MX (1) MX2015007563A (en)
PE (1) PE13262015A1 (en)
PH (1) PH12015501156A1 (en)
SG (2) SG11201503807TA (en)
WO (1) WO2014093941A1 (en)
ZA (1) ZA201503594B (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3387B1 (en) 2011-12-16 2019-03-13 Glaxosmithkline Llc Derivatives of betulin
US9795619B2 (en) * 2012-12-14 2017-10-24 Glaxosmithkline Llc Pharmaceutical compositions
JP6028105B2 (en) 2012-12-21 2016-11-16 ギリアード サイエンシス インコーポレーテッド Polycyclic carbamoylpyridone compound and pharmaceutical use thereof
US9637516B2 (en) 2012-12-31 2017-05-02 Hetero Research Foundation Betulinic acid proline derivatives as HIV inhibitors
NO2865735T3 (en) 2013-07-12 2018-07-21
DK3019503T3 (en) 2013-07-12 2017-11-20 Gilead Sciences Inc Polycyclic-carbamoylpyridon compounds and its uses for treating hiv infections
NO2717902T3 (en) 2014-06-20 2018-06-23
TW201613936A (en) 2014-06-20 2016-04-16 Gilead Sciences Inc Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
US20170129916A1 (en) 2014-06-26 2017-05-11 Hetero Research Foundation Novel betulinic proline imidazole derivatives as hiv inhibitors
CA2961528A1 (en) * 2014-09-26 2016-03-31 Glaxosmithkline Intellectual Property (No.2) Limited Long acting pharmaceutical compositions
TW201636347A (en) 2014-12-23 2016-10-16 Gilead Sciences Inc A multi-acyl cyclic amine pyridone compounds and pharmaceutical use
CU20170102A7 (en) 2015-02-09 2018-01-10 Hetero Labs Ltd New triterpenona derivative c-3 c-reverse amide 17 as inhibitors of HIV
WO2016147099A2 (en) 2015-03-16 2016-09-22 Hetero Research Foundation C-3 novel triterpenone with c-28 amide derivatives as hiv inhibitors
KR20190057158A (en) 2015-04-02 2019-05-27 길리애드 사이언시즈, 인코포레이티드 Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
WO2018042331A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof
WO2018042332A1 (en) * 2016-08-31 2018-03-08 Glaxosmithkline Intellectual Property (No.2) Limited Combinations and uses and treatments thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8815265D0 (en) 1988-06-27 1988-08-03 Wellcome Found Therapeutic nucleosides
US5358721A (en) * 1992-12-04 1994-10-25 Alza Corporation Antiviral therapy
AU6248901A (en) 2000-05-23 2001-12-03 Univerzita Palackeho V Olomouc Triterpenoid derivatives
US7163700B2 (en) * 2001-07-31 2007-01-16 Capricorn Pharma, Inc. Amorphous drug beads
US20080206161A1 (en) * 2002-10-25 2008-08-28 Dov Tamarkin Quiescent foamable compositions, steroids, kits and uses thereof
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
WO2005112929A2 (en) * 2004-05-20 2005-12-01 Cornell Research Foundation, Inc. Anti-hiv-1 activity of betulinol derivatives
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
CN1682740A (en) * 2005-03-11 2005-10-19 中国药科大学 Use of pentacylic triterpene compounds in preparing glycogenic phosphorylase inhibitor
WO2006105356A2 (en) 2005-03-29 2006-10-05 Regents Of The University Of Minnesota Methods of manufacturing bioactive 3-esters of betulinic aldehyde and betulinic acid
TWI457136B (en) 2005-04-04 2014-10-21 Tibotec Pharm Ltd Prevention of hiv-infection
WO2006117666A2 (en) * 2005-04-29 2006-11-09 Pfizer Inc. Dosage forms, pharmaceutical compositions and methods for sub-tenon delivery
EP1986654A2 (en) 2006-02-21 2008-11-05 Achillion Pharmaceuticals, Inc. Substituted taraxastanes useful for treating viral infections
FI121468B (en) 2006-06-07 2010-11-30 Valtion Teknillinen Compounds derived from betulin as antimicrobial agents
SI2040671T1 (en) 2006-06-23 2018-05-31 Janssen Sciences Ireland Uc Aqueous suspensions of tmc278
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
CA2668452A1 (en) 2006-11-03 2008-05-15 Panacos Pharmaceuticals, Inc. Extended triterpene derivatives
JP5701057B2 (en) * 2007-07-12 2015-04-15 ヤンセン サイエンシズ アイルランド ユーシー (E) Crystalline form of 4-[[4-[[4- (2-cyanoethenyl) -2,6-dimethylphenyl] amino] -2-pyrimidinyl] amino] benzonitrile
AU2008342537A1 (en) 2008-01-03 2009-07-09 Virochem Pharma Inc. Novel lupane derivatives
CN101977924A (en) * 2008-01-03 2011-02-16 Viro化学制药公司 Novel c-21-keto lupane derivatives preparation and use thereof
DE102008037025C5 (en) * 2008-08-08 2016-07-07 Jesalis Pharma Gmbh Process for the preparation of crystalline drug microparticles or a solid state drug particle form
US8778990B2 (en) 2008-11-04 2014-07-15 Trustees Of Dartmouth College Betulinic acid derivatives and methods of use thereof
CZ2008723A3 (en) 2008-11-13 2010-01-13 Univerzita Palackého v Olomouci 2-Deoxyglycosides of triterpenoids, process of their preparation and their use as medicament
CA2744019C (en) * 2008-12-11 2017-03-14 Shionogi & Co., Ltd. Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates
US8802727B2 (en) 2009-07-14 2014-08-12 Hetero Research Foundation, Hetero Drugs Limited Pharmaceutically acceptable salts of betulinic acid derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
BR112012019762A2 (en) * 2010-02-11 2016-02-23 Glaxosmithkline Llc compound, composition, and method for treating a disease.
TWI577377B (en) * 2010-09-16 2017-04-11 Viiv醫療保健公司 Pharmaceutical compositions
WO2013020245A1 (en) 2011-08-08 2013-02-14 Glaxosmithkline Llc Carbonyl derivatives of betulin
WO2013020246A1 (en) 2011-08-08 2013-02-14 Glaxosmithkline Llc Methylene derivatives of betulin
EP2791102B1 (en) 2011-12-14 2016-05-18 Glaxosmithkline LLC Propenoate derivatives of betulin
JO3387B1 (en) * 2011-12-16 2019-03-13 Glaxosmithkline Llc Derivatives of betulin
WO2014035945A1 (en) 2012-08-28 2014-03-06 Glaxosmithkline Llc Pharmaceutical compositions
US9795619B2 (en) * 2012-12-14 2017-10-24 Glaxosmithkline Llc Pharmaceutical compositions
CA2961528A1 (en) 2014-09-26 2016-03-31 Glaxosmithkline Intellectual Property (No.2) Limited Long acting pharmaceutical compositions

Also Published As

Publication number Publication date
EA201590862A1 (en) 2016-05-31
AU2013358897B2 (en) 2017-01-05
US20180042944A1 (en) 2018-02-15
US9795619B2 (en) 2017-10-24
EP2931285A1 (en) 2015-10-21
CR20150313A (en) 2015-10-19
IL238807D0 (en) 2015-06-30
SG10201704467SA (en) 2017-06-29
HK1209638A1 (en) 2016-04-08
EP2931285A4 (en) 2016-06-01
CL2015001660A1 (en) 2015-10-02
CA2893959A1 (en) 2014-06-19
ZA201503594B (en) 2018-11-28
MX2015007563A (en) 2015-10-14
AU2013358897A1 (en) 2015-07-02
CN104902905A (en) 2015-09-09
MA38182A1 (en) 2018-04-30
JP2016503030A (en) 2016-02-01
PH12015501156A1 (en) 2015-08-10
KR20150093819A (en) 2015-08-18
US20150313917A1 (en) 2015-11-05
WO2014093941A1 (en) 2014-06-19
BR112015013695A2 (en) 2017-07-11
SG11201503807TA (en) 2015-06-29

Similar Documents

Publication Publication Date Title
ECSP066730A (en) Compounds and methods for use
PH12015501445B1 (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
MA35348B1 (en) 4-imidazopyridazin-1-yl-benzamide and 4-imidazotriazin-1-yl-benzamide as inhibitors of btk
CR20150371A (en) PRMT5 inhibitors and their uses
UA111770C2 (en) inhibitors bromdomenu
UY31470A1 (en) Quinoxaline-containing compounds as inhibitors of the Hepatitis C virus
CL2014000919A1 (en) derivatives acid compounds 2- tert -butoxy-2- (5-methylbenzo [d] thiazol-6-yl) acetic acid; pharmaceutical composition which comprises; method of treating an HIV infection; and its use to treat HIV infection.
AU2012242871A8 (en) Fused imidazole derivatives useful as IDO inhibitors
CL2015001864A1 (en) Compounds derived espiropirido [1,2-a] pyrazine substituted, as inhibitors of HIV integrase; pharmaceutical composition which comprises; and its use for the prophylaxis or treatment of HIV infection.
SV2011004077A (en) Aminobutyric substituted derivatives as inhibitors of neprilysin
CL2011002053A1 (en) pharmaceutical composition spray foam in oil in water emulsion comprising, organic solvent, surfactant component, and propellant pharmaceutically active agent, water, oil; preparation process; use for treating diseases or conditions achieve skin.
UA113956C2 (en) Pyrimidine derivatives for the treatment of viral infections
GT201400164A (en) Compounds imidazopirrolidinona
CU20120176A7 (en) Modulatory compounds capable of inhibiting immunosuppression signaling path programmed cell death 1
CL2012002489A1 (en) Compounds derived naphtho-imidazole silyl; pharmaceutical composition; and their use to prevent or treat an infection by Hepatitis C virus.
ECSP13012418A (en) Derivatives -quinolin-acetic acid 2 as antiviral compounds to HIV
CR10192A (en) Amido compounds and their use as pharmaceuticals
CO6571891A2 (en) Inhibitors the Hepatitis C virus.
ECSP13012417A (en) Acid derivatives Napht-2-ylacetic for treating AIDS
CL2015002335A1 (en) 2-aminopyrimidine derivatives to treat viral infections.
MX2011011514A (en) Formulations of cannabidiol and methods of using the same.
CR20130560A (en) Bezotiazol compounds and pharmaceutical use
DOP2014000260A (en) D-amino acid compounds to liver disease
CO6470847A2 (en) Substituted amino derivatives as inhibitors propionic neprilysin
ECSP12012111A (en) Pyrrolo-pyrimidine as inhibitors of CDK4 / 6

Legal Events

Date Code Title Description
FD Application declared void or lapsed